Superseded public profile

FDA-approved↗Metabolic↗

Superseded · version 4: Tirzepatide↗

Related names recorded in this version: Zepbound, Mounjaro↗

A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

We refreshed this profile's label citation to the reviewed SPL version 40, published 2026-09-02. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope. 1

What this version reported

The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗

Sources for this version

  1. 1
    ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  2. 2
    FDA approves tirzepatide for chronic weight management ↗

    U.S. Food and Drug Administration · Official source · Source checked July 22, 2026

  3. 3
    Tirzepatide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked July 29, 2026